Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

Dry Eye Clinical Trial

Official title:

Comparative Study of Thymosin Beta 4 Eye Drops or Vehicle in the Treatment of Patients With Ocular Surface Defects Due to Severe Dry Eye

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01393132
• Other study ID #: 1003008179
• Status: Completed
• Phase: Phase 2
• First received: July 7, 2011
• Last updated: December 21, 2015
• Start date: March 2011
• Est. completion date: December 2012

Study information

• Verified date: December 2015
• Source: Michigan Cornea Consultants, PC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Severe dry eye is a debilitating ocular disease resulting in loss of vision, reduced day-to-day function and significant discomfort. Tear substitutes are an important part of the treatment of all patients, however, even with aggressive us, the corneal(ocular)surface often remains very irregular due to poor surface healing.

The agent being evaluated in this study, Thymosin Beta 4, promotes healing of the corneal surface and has been studied in patients with recalcitrant corneal ulcers and erosions with significant success (Arch Ophthalmol. 2010;128(5):636-638., Ann of the NY Acad of Sci, May, 2010).

The study hypothesis is that Thymosin Beta 4, in its role as a modulator of corneal surface healing, may be able to promote healing of the corneal surface allowing for more conventional modalities to take over and maintain a smooth and regular ocular surface. The investigators hope to be able to demonstrate an improvement in visual acuity, surface healing and a reduction in dry-eye related symptoms.

Description:

See above

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Schirmers of < 5 mm at 5 minutes

• TFBUT: less than 10 seconds

• Corneal staining of >3 of 15: conjunctival staining of >3 of 18

• Ocular Surface Disease Index of > 50

• Presumed best corrected vision of 20/60 or better

Exclusion Criteria:

• Acute or inflammatory corneal disease

• Pregnancy or lactation

• Monocular status

• Punctal occlusion within 30 days

• Ocular surgery within 3 months

• Corneal thinning of >50%

• Active corneal infection

• History of ocular malignancy

• Retinal neovascularization

• Current use of topical cyclosporin A

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dry Eye
• Dry Eye Syndromes
• Graft vs Host Disease
• Graft vs. Host Disease
• Keratoconjunctivitis Sicca
• Sjogren's Syndrome

Intervention

Drug:
• Thymosin Beta 4 eye drops
Patients will be randomized and will receive the same eye drops the Thymosin Beta 4.
• Vehicle Control
Patients will be randomized and will receive the same eye drops without the Thymosin Beta 4.

Locations

Country	Name	City	State
United States	Michigan Cornea Consultants, P.C.	Southfield	Michigan

Sponsors (2)

Lead Sponsor	Collaborator
Michigan Cornea Consultants, PC	Kresge Eye Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety	Sum of adverse events observed at Day 1, Day 14, Day 28 and Day 56. Measurable by Intra-ocular pressure (IOP) by applanation tonometry, Complete ophthalmologic evaluation including fundoscopy, An adverse event (baseline and all subsequent study visits).	Day 1, Day 14, Day 28 and Day 56	No
Secondary	Corneal Fluorescein Staining	Ocular surface irregularity as measured by Slit Lamp Examination (SLE) with fluorescein dye staining of the cornea at days 56 (+28 day follow up).; The scale used to determine the difference in corneal fluorescein staining is the Oxford scale. (The Oxford Scale measures corneal fluorescein staining) Corneal staining type was assessed by the investigator for each of 5 regions of the cornea, i.e., four quadrants plus central. The five regions were summed, for a maximum score of 25. A higher score represents greater disability.	Days 56 (+28 day follow up)	No
Secondary	Ocular Discomfort Index	Dry eye causes ocular discomfort, which is measured using a Ocular Surface Disease Index at 56 day (+28 day followup).; (Symptomatic improvement using the validated Ocular Surface Disease Index (OSDI).; The OSDI is a questionnaire that consists of 12 questions about ocular irritation and the effect of dry eye on vision.; For every question, participants check a score between 0 and 4, where 0 equals "none of the time" and 4 equals "all of the time.; OSDI scores are calculated according to: OSDI = [(sum of scores for all questions answered)*100] / [(total number of questions answered)*4].; The OSDI is scored on a scale of 0 to 100, with higher scores representing greater disability.	Days 56 (+28 day follow up)	No
Secondary	Tear Film Break up Time	Tear film break up time (TFBUT) was measured to evaluating the quality of tear at 56 day (+28 day follow up).; The tear film break-up time is defined as the interval between the last complete blink and the first appearance of a dry spot, or disruption in the tear film.; Range : >10 seconds is thought to be normal, <5 seconds low (with high likelihood of dry eye symptoms).	Days 56 (+28 day follow up)	No